SURMONTIL- trimipramine maleate capsule United States - English - NLM (National Library of Medicine)

surmontil- trimipramine maleate capsule

teva women's health, inc. - trimipramine maleate (unii: 269k6498ld) (trimipramine - unii:6s082c9ndt) - trimipramine 25 mg - surmontil is indicated for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. in studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. in hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. the use of maois intended to treat psychiatric disorders with surmontil or within 14 days of stopping treatment with surmontil is contraindicated because of an increased risk of serotonin syndrome. the use of surmontil within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting surmontil in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (

Trimipramine 50mg capsules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

trimipramine 50mg capsules

alliance healthcare (distribution) ltd - trimipramine maleate - oral capsule - 50mg

Trimipramine 25mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

trimipramine 25mg tablets

alliance healthcare (distribution) ltd - trimipramine maleate - oral tablet - 25mg

Trimipramine 25mg tablets United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

trimipramine 25mg tablets

phoenix healthcare distribution ltd - trimipramine maleate - oral tablet - 25mg